Plain-English translation of NCT02843945 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new device called CivaSheet that doctors implant directly into the pancreas during cancer surgery. The device delivers a special type of radiation (using Palladium-103) that targets only the area where the cancer was removed, rather than spreading radiation to surrounding healthy tissue. Researchers hope this focused approach will reduce the chance of cancer coming back without causing additional side effects.
Pancreatic cancer that hasn't spread to other parts of the body is sometimes treated with surgery followed by radiation, but traditional radiation can damage nearby organs and tissues. This trial exists to see if the new treatment's ability to aim radiation in one direction can deliver stronger doses exactly where needed while protecting healthy organs nearby.
You likely qualify if…
You likely don't qualify if…
If you join this study, you would undergo your planned pancreatic cancer surgery as usual, and at the time of surgery, the surgeon would implant the CivaSheet device in the area where the cancer was removed. After surgery, you would have follow-up visits to monitor your recovery, check how well the implant is working, and watch for any side effects. The study will track how safe the device is and whether it helps prevent cancer from returning.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States